Biomarkers of Immunosuppressant Therapy Resistance in Primary FSGS
| Main study | Novel Therapies to Treat Resistant Focal Segmental Glomerulosclerosis: Phase II Clinical Trial |
|---|---|
| Contact name | Robert Woronieki, MD |
| Contact phone | 718-655-1120 |
| Contact email | rworonie@aecom.yu.edu |